Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 7/2018

08.05.2018 | Original Article

VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival

verfasst von: Lawrence F. Kuklinski, Shaofeng Yan, Zhongze Li, Jan L. Fisher, Chao Cheng, Randolph J. Noelle, Christina V. Angeles, Mary Jo Turk, Marc S. Ernstoff

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Adaptive immune responses contribute to the pathogenesis of melanoma by facilitating immune evasion. V-domain Ig suppressor of T-cell activation (VISTA) is a potent negative regulator of T-cell function and is expressed at high levels on monocytes, granulocytes, and macrophages, and at lower densities on T-cell populations within the tumor microenvironment. In this study, 85 primary melanoma specimens were selected from pathology tissue archives and immunohistochemically stained for CD3, PD-1, PD-L1, and VISTA. Pearson’s correlation coefficients identified associations in expression between VISTA and myeloid infiltrate (r = 0.28, p = 0.009) and the density of PD-1+ inflammatory cells (r = 0.31, p = 0.005). The presence of VISTA was associated with a significantly worse disease-specific survival in univariate analysis (hazard ratio = 3.57, p = 0.005) and multivariate analysis (hazard ratio = 3.02, p = 0.02). Our findings show that VISTA expression is an independent negative prognostic factor in primary cutaneous melanoma and suggests its potential as an adjuvant immunotherapeutic intervention in the future.
Literatur
1.
Zurück zum Zitat Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16(1):5–24CrossRefPubMedPubMedCentral Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16(1):5–24CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Geller AC, Zhang Z, Sober AJ, Halpern AC, Weinstock MA, Miller DR et al (2003) The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985–1999. J Am Acad Dermatol 48(1):34–41CrossRefPubMed Geller AC, Zhang Z, Sober AJ, Halpern AC, Weinstock MA, Miller DR et al (2003) The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985–1999. J Am Acad Dermatol 48(1):34–41CrossRefPubMed
3.
Zurück zum Zitat Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J et al (2011) Recent trends in the cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol 65(5 Suppl 1):S17–S25 (e1–3)PubMed Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J et al (2011) Recent trends in the cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol 65(5 Suppl 1):S17–S25 (e1–3)PubMed
4.
Zurück zum Zitat Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622–3634CrossRefPubMed Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622–3634CrossRefPubMed
5.
Zurück zum Zitat Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303–1310CrossRefPubMed Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303–1310CrossRefPubMed
6.
Zurück zum Zitat Clark WH Jr, From L, Bernardino EA et al (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29(3):705–727PubMed Clark WH Jr, From L, Bernardino EA et al (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29(3):705–727PubMed
7.
Zurück zum Zitat Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW et al (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sential lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30(21):2678–2683CrossRefPubMed Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW et al (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sential lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30(21):2678–2683CrossRefPubMed
8.
Zurück zum Zitat Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL et al (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127ra37CrossRefPubMedPubMedCentral Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL et al (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127ra37CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al (2000) Engagement of PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034CrossRefPubMedPubMedCentral Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al (2000) Engagement of PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y et al (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208(3):577–592CrossRefPubMedPubMedCentral Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y et al (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208(3):577–592CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S et al (2014) VISTA is an immune checkpoint molecule for human T cells. Cancer Res 74(7):1924–1932CrossRefPubMedPubMedCentral Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S et al (2014) VISTA is an immune checkpoint molecule for human T cells. Cancer Res 74(7):1924–1932CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Flies DB, Wang S, Xu H, Chen L (2011) Cutting edge: a monoclonal antibody specific for programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol 187(4):1537–1541CrossRefPubMedPubMedCentral Flies DB, Wang S, Xu H, Chen L (2011) Cutting edge: a monoclonal antibody specific for programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol 187(4):1537–1541CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Lines JL, Sempere LF, Broughton T, Wang L, Noelle R (2014) VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2(6):510–517CrossRefPubMedPubMedCentral Lines JL, Sempere LF, Broughton T, Wang L, Noelle R (2014) VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2(6):510–517CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P et al (2014) VISTA regulates the development of protective antitumor immunity. Cancer Res 74(7):1933–1944CrossRefPubMed Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P et al (2014) VISTA regulates the development of protective antitumor immunity. Cancer Res 74(7):1933–1944CrossRefPubMed
15.
Zurück zum Zitat Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C et al (2005) The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104(6):1246–1254CrossRefPubMed Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C et al (2005) The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104(6):1246–1254CrossRefPubMed
17.
Zurück zum Zitat Wu L, Deng WW, Huang CF, Bu LL, Yu GT, Lao L et al (2017) Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother 66(5):627–636CrossRefPubMed Wu L, Deng WW, Huang CF, Bu LL, Yu GT, Lao L et al (2017) Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother 66(5):627–636CrossRefPubMed
18.
Zurück zum Zitat Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III and IV melanoma. N Engl J Med 377(19):1824–1835CrossRefPubMed Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III and IV melanoma. N Engl J Med 377(19):1824–1835CrossRefPubMed
19.
Zurück zum Zitat Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375(19):1845–1855CrossRefPubMedPubMedCentral Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375(19):1845–1855CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275–287CrossRefPubMedPubMedCentral Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275–287CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T et al (2010) Tumor expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757–1766CrossRefPubMed Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T et al (2010) Tumor expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116(7):1757–1766CrossRefPubMed
23.
Zurück zum Zitat Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M et al (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig 94(1):107–116CrossRefPubMed Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M et al (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig 94(1):107–116CrossRefPubMed
24.
Zurück zum Zitat Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114(8):1537–1544CrossRefPubMedPubMedCentral Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114(8):1537–1544CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Oba J, Nakahara T, Abe T, Hagihara A, Moroi Y, Furue M (2014) Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival. J Am Acad Dermatol 70(5):954–956CrossRefPubMed Oba J, Nakahara T, Abe T, Hagihara A, Moroi Y, Furue M (2014) Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival. J Am Acad Dermatol 70(5):954–956CrossRefPubMed
26.
Zurück zum Zitat Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571CrossRefPubMedPubMedCentral Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J et al (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28(3):245–253CrossRefPubMed Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J et al (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28(3):245–253CrossRefPubMed
28.
Zurück zum Zitat Wang Q, He J, Flies DB, Luo L, Chen L (2017) Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability. Sci Rep 7(1):6086CrossRefPubMedPubMedCentral Wang Q, He J, Flies DB, Luo L, Chen L (2017) Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability. Sci Rep 7(1):6086CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD et al (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci USA 112(21):6682–6687CrossRefPubMedPubMedCentral Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD et al (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci USA 112(21):6682–6687CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Gadiot J, Hoojikaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117(10):2192–2201CrossRefPubMed Gadiot J, Hoojikaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117(10):2192–2201CrossRefPubMed
31.
Zurück zum Zitat Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS et al (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381–3385CrossRefPubMed Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS et al (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381–3385CrossRefPubMed
32.
Zurück zum Zitat Tsang JY, Au WL, Lo KY, Ni YB, Hlaing T, Hu J et al (2017) PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Res Treat 162(1):19–30CrossRefPubMed Tsang JY, Au WL, Lo KY, Ni YB, Hlaing T, Hu J et al (2017) PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Res Treat 162(1):19–30CrossRefPubMed
33.
Zurück zum Zitat Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H et al (2016) Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci USA 113(48):E7769–E7777CrossRefPubMedPubMedCentral Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H et al (2016) Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci USA 113(48):E7769–E7777CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Kakavand H, Jacket LA, Menzies AM, Gide TN, Carlino MS, Saw RPM et al (2017) Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol 30(12):1666–1676CrossRefPubMed Kakavand H, Jacket LA, Menzies AM, Gide TN, Carlino MS, Saw RPM et al (2017) Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol 30(12):1666–1676CrossRefPubMed
Metadaten
Titel
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
verfasst von
Lawrence F. Kuklinski
Shaofeng Yan
Zhongze Li
Jan L. Fisher
Chao Cheng
Randolph J. Noelle
Christina V. Angeles
Mary Jo Turk
Marc S. Ernstoff
Publikationsdatum
08.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 7/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-018-2169-1

Weitere Artikel der Ausgabe 7/2018

Cancer Immunology, Immunotherapy 7/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.